SCHEMBL5002852

SCHEMBL5002852

CCCCC[CH]OC(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
CES2 O00748 3/20 0.47
CES1 P23141 3/20 0.47
NAAA Q02083 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 3/20 0.44
PRKCA P17252 3/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 1/20 0.42
F2 P00734 1/20 0.42
SOAT2 O75908 1/20 0.42
SOAT1 P35610 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21693932 0.98 CES2 (0.49) LMNACES2CES1NAAATDP1
SCHEMBL4189905 0.88 LMNA (0.55) LMNACES2CES1TDP1TSHR
SCHEMBL6551288 0.84 LMNA (0.47) LMNACES2CES1TDP1TSHR
SCHEMBL22439055 0.83 SOAT2 (0.49) LMNACES2CES1NAAATDP1
SCHEMBL21528269 0.83 SOAT2 (0.49) LMNACES2CES1NAAATDP1
SCHEMBL6552841 0.83 SOAT2 (0.49) LMNACES2CES1NAAATDP1
SCHEMBL6552638 0.83 SOAT2 (0.49) LMNACES2CES1NAAATDP1
SCHEMBL6552826 0.83 SOAT2 (0.49) LMNACES2CES1NAAATDP1
SCHEMBL6552788 0.83 SOAT2 (0.49) LMNACES2CES1NAAATDP1
SCHEMBL6552573 0.83 SOAT2 (0.49) LMNACES2CES1NAAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111385-B1 Substituted alkine derivatives as anti-cancer agents UNIV LOUISVILLE RES FOUND (US) 2014-11-12 EP disclosed
US-8703829-B2 Therapeutic compounds UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2014-04-22 US disclosed
EP-2567950-A1 Substituted alkine derivatives as anti-cancer agents University Of Louisville Research Foundation, Inc. (US) 2013-03-13 EP disclosed
US-20120329866-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2012-12-27 US disclosed
US-8207381-B2 1-Bromo-1,1-difluoro-non-2-yn-4-ol; 6-Bromo-6,6-difluoro-2,2-dimethyl-hex-4-yn-3-ol; anticarcinogenic, -tumor, -metastasic agents; enzyme inhibitors of modification methylases; myelodysplastic syndrome, leukemia, a solid tumor, schizophrenia, sickle cell disease, or lupus; breast, colon, brain cancers UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2012-06-26 US disclosed
US-20080188570-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2008-08-07 US disclosed
US-4496447-A PHOTOPOLYMERIZATION OF UNSATURATED COMPOUNDS AND FOR CURING PRINTING INKS MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1985-01-29 US disclosed
US-4374984-A Aromatic-aliphatic ketones useful as photoinitiators MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188570-A1 THERAPEUTIC COMPOUNDS ABCB1, NQO1, ABCB11 LMNA 1586/4885CES2 100/4885CES1 445/4885
US-20120329866-A1 THERAPEUTIC COMPOUNDS ABCB1, MCL1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 LMNA 1925/4885CES2 73/4885CES1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.